It’s health.
Most investors ask: Will my assets last as long as I live?
Far fewer ask: How many of those years will I remain cognitively sharp, physically capable, and able to live as I choose?
That distinction matters.
A long life lived in poor health is not only emotionally costly. It is financially destabilizing. Late-stage illness can quickly erode even the most carefully constructed wealth strategy.
Chronic disease now drives 90% of healthcare costs in the United States. Yet many of these conditions develop silently for years before symptoms appear. By the time traditional medicine intervenes, options are often narrower and more expensive.
This is where medicine is changing.
Advances in genomics, imaging, and molecular biomarkers now allow clinicians to detect disease signals earlier than ever before. Instead of waiting for decline, we can establish baselines, monitor subtle shifts, and intercept risk before it alters the trajectory of our healthspan, which is the number of years a person remains cognitively sharp, physically capable, and able to live independently.
One clear example of how scientific advancement is changing care is Alzheimer’s disease. For years, it was widely viewed as an inevitable diagnosis identified only after meaningful cognitive decline. Today, that assumption is being challenged. Emerging diagnostics and therapies suggest that earlier identification and intervention can meaningfully slow progression in appropriate patients.
The approach increasingly resembles the NFL’s concussion protocol. You establish a precise baseline using imaging, blood-based biomarkers, and cognitive assessment. You monitor carefully over time. And at the first sign of deviation from baseline, you intervene.
That shift is significant. When disease is identified early in its course, certain therapies have demonstrated the ability to slow progression. Slowing progression does not eliminate disease. But it can preserve cognitive clarity and independence for longer. From a financial planning standpoint, the preservation of decision-making capacity and autonomy can materially affect long-term care costs, estate timing, and intergenerational planning.
Preserving healthy, functional years does more than improve quality of life. It materially alters long-term care costs, estate outcomes, and the preservation of intergenerational wealth.
At Radence, we integrate advanced diagnostics, continuous monitoring, and personalized care coordination into a structured, science-driven model. Our goal is not simply to extend lifespan. It is to bring clarity to risk, offer control, and help preserve more healthy, functional years. It is to help members spend more of their years in peak health.
Investors expect their advisors to anticipate financial risk before it appears on a balance sheet.
The most forward-thinking individuals are beginning to treat health as a measurable, managed variable within long-term strategy.
If you’d like to learn how Radence approaches early detection and precision prevention, we welcome a private conversation.



